The regulator said it had found several violations with regard to current good manufacturing practices (CGMP) at three of its plants.
"At Dr Reddy's Laboratories' facilities, we identified significant deviations from CGMP for manufacturing of active pharmaceutical ingredients (APIs)... We found significant violations of CGMP regulations for finished pharmaceuticals," US FDA noted.
"FDA strongly recommends that you evaluate global manufacturing operations to ensure compliance with CGMP regulations and requirements, comprehensively and immediately," the regulator said in its letter on November 5 addressed to Satish Reddy, DRL Chairman.
"If you fail to correct these violations, under Section 801(a)(3) of the FD&C Act, 21 USC 381(a)(3), FDA may also refuse admission of articles into the United States...," it cautioned.
Also Read
Earlier this month, the country's second-largest drug maker received a warning letter from the US drug regulator relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana.
In response to the letter, DRL CEO G V Prasad had said the company is in the process of shifting some of the products from these plants to other facilities and considering third party assessment for its plants.
(REOPENS BCM 6)
When contacted a DRL spokesperson said they are in the process of replying to USFDA's observations and will do so within the stipulated time.
The regulator has set a deadline for company to respond within 15 days from the date of receiving the letter.